| Literature DB >> 34429328 |
Sharon Grisaru-Tal1, Shai Dulberg2, Lir Beck3, Chunyan Zhang4, Michal Itan1, Soroor Hediyeh-Zadeh5,6, Julie Caldwell7, Perri Rozenberg1, Avishay Dolitzky1, Shmuel Avlas1, Inbal Hazut1, Yaara Gordon1, Ophir Shani2, Shlomo Tsuriel8, Motti Gerlic1, Neta Erez2, Nicolas Jacquelot5,9, Gabrielle T Belz5,6,10, Marc E Rothenberg7, Melissa J Davis5,6, Hua Yu4, Tamar Geiger3, Asaf Madi2, Ariel Munitz11.
Abstract
The recognition of the immune system as a key component of the tumor microenvironment (TME) led to promising therapeutics. Because such therapies benefit only subsets of patients, understanding the activities of immune cells in the TME is required. Eosinophils are an integral part of the TME especially in mucosal tumors. Nonetheless, their role in the TME and the environmental cues that direct their activities are largely unknown. We report that breast cancer lung metastases are characterized by resident and recruited eosinophils. Eosinophil recruitment to the metastatic sites in the lung was regulated by G protein-coupled receptor signaling but independent of CCR3. Functionally, eosinophils promoted lymphocyte-mediated antitumor immunity. Transcriptome and proteomic analyses identified the TME rather than intrinsic differences between eosinophil subsets as a key instructing factor directing antitumorigenic eosinophil activities. Specifically, TNFα/IFNγ-activated eosinophils facilitated CD4+ and CD8+ T-cell infiltration and promoted antitumor immunity. Collectively, we identify a mechanism by which the TME trains eosinophils to adopt antitumorigenic properties, which may lead to the development of eosinophil-targeted therapeutics. SIGNIFICANCE: These findings demonstrate antitumor activities of eosinophils in the metastatic tumor microenvironment, suggesting that harnessing eosinophil activity may be a viable clinical strategy in patients with cancer. ©2021 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34429328 DOI: 10.1158/0008-5472.CAN-21-0839
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701